Professor of Medicine
Rheumatology
Dr. Bevra H. Hahn, MD
|
|
Give Review
Bevra Hahn works in the field of Rheumatology. She studied medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care She received 6 awards: "CMS Meaningful Use Stage 1 Certification", "Elected Member", "Johns Hopkins Society of Scholars", "Gold Medal", "Awards/Medals" and "Super Doctor". Bevra Hahn has written publications. She has 66 publications published with PubMed. The lastest paper is: 'Paraoxonase-3 Is Depleted from the High-Density Lipoproteins of Autoimmune Disease Patients with Subclinical Atherosclerosis.' Bevra Hahn is registered with Medicare.
Publications
- Paraoxonase-3 Is Depleted from the High-Density Lipoproteins of Autoimmune Disease Patients with Subclinical Atherosclerosis.
- Th17 Cells in inflammation and autoimmunity.
- JLab Measurement of the He4 Charge Form Factor at Large Momentum Transfers.
- Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune Cells.
- A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic Lupus erythematosus.
- Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression.
- The role of miRNA in inflammation and autoimmunity.
- Blockade of Programmed Death-1 in Young (New Zealand Black x New Zealand White)F1 Mice Promotes the Suppressive Capacity of CD4+ Regulatory T Cells Protecting from Lup...
- Belimumab for systemic Lupus erythematosus.
- Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic Lupus erythematosus in multiple ancestral groups.
- MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus.
- Plasma levels of osteopontin identify patients at risk for organ damage in systemic Lupus erythematosus.
- American College of Rheumatology guidelines for screening, treatment, and management of Lupus nephritis.
- Genes, tolerance and systemic autoimmunity.
- Tolerance induced by anti-DNA Ig peptide in (NZB??NZW)F(1) lupus mice impinges on the resistance of effector T Cells to suppression by regulatory T Cells.
- Regulatory T Cells in systemic lupus erythematosus (SLE); Role of peptide tolerance.
- High plasma leptin levels confer increased risk of atherosclerosis in women with systemic Lupus erythematosus, and are associated with inflammatory oxidised lipids.
- Association of a functional IRF7 variant with systemic Lupus erythematosus.
- Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T Cells that protect from lupus-like d...
- Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production.
- Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic Lupus erythematosus.
- Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic Lupus erythematosus patients to predict risk of atherosclerosis?
- Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic Lupus erythematosus.
- Cutting edge: Regulatory T Cells directly suppress B Cells in systemic lupus erythematosus.
- Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic Lupus erythematosus.
- Modulation of p38 MAPK activity in regulatory T Cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice.
- Novel autoantibodies against the activated coagulation factor IX (FIXa) in the Antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
- Induction of immune tolerance by activation of CD8+ T suppressor/regulatory Cells in lupus-prone mice.
- Cutaneous vasculitis in breast cancer treated with chemotherapy.
- Anti-DNA Ig peptides promote Treg Cell activity in systemic lupus erythematosus patients.
- pConsensus peptide induces tolerogenic CD8+ T Cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules.
- Gene vaccination for the induction of Immune tolerance.
- CD8+ T Cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression.
- Protection against renal Disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
- Some Antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.
- Association of a common complement receptor 2 haplotype with increased risk of systemic Lupus erythematosus.
- Impact of the Medicare Short Stay Transfer Policy on patients undergoing major orthopedic surgery.
- The complexity of care for patients with rheumatoid Arthritis: metrics for better understanding chronic disease care.
- Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss.
- Antibodies against the activated coagulation factor X (FXa) in the Antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.
- Association of increased interferon-inducible gene expression with Disease activity and lupus nephritis in patients with systemic lupus erythematosus.
- Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid Arthritis.
- Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial Cells.
- Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T Cell suppressors.
- Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the Antiphospholipid syndrome.
- Maternal HLA class II compatibility in men with systemic Lupus erythematosus.
- Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic Lupus erythematosus families: increased T allele frequency in systemi...
- A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic Lupus erythematosus.
- The effect of combined estrogen and progesterone hormone replacement therapy on Disease activity in systemic lupus erythematosus: a randomized trial.
- Cellular and molecular mechanisms of regulation of autoantibody production in lupus.
- Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T Cells.
- Systemic Lupus erythematosus genome scan: support for linkage at 1q23, 2q33, 16q12-13, and 17q21-23 and novel evidence at 3p24, 10q23-24, 13q32, and 18q22-23.
- Ig-reactive CD4+CD25+ T Cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA.
- Development and evaluation of a patient self-report case-finding method for rheumatoid Arthritis.
- Identification of anti-plasmin antibodies in the Antiphospholipid syndrome that inhibit degradation of fibrin.
- Systemic Lupus erythematosus and accelerated atherosclerosis.
- A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C.
- Identification and characterization of a peptide mimetic that may detect a species of Disease-associated anticardiolipin antibodies in patients with the antiphospholip...
- Identification and characterization of SmD183-119-reactive T Cells that provide T Cell help for pathogenic anti-double-stranded DNA antibodies.
- Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic Lupus erythematosus.
- Familiality and co-occurrence of clinical features of systemic Lupus erythematosus.
- Improving joint disease in patients with rheumatoid Arthritis: is this enough to treat the accompanying dyslipidemias?
- Induction of autoantibody production is limited in nonautoImmune mice.
- Gouty tophi in a pancreatic pseudocyst.
- Can Women with Systemic Lupus Erythematosus Safely Use Exogenous Estrogens?
Schools
Johns Hopkins University School Of Medicine
Wash University Barnes Hospital
Johns Hopkins
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
- Trigger Point Injection
- View All
Conditions Treated
- Adhesive Capsulitis
- Antiphospholipid Syndrome (APS)
- Arthritis
- Bursitis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
- Johns Hopkins Society of Scholars
- Gold Medal
- Awards/Medals
- Super Doctor
Education
-
Johns Hopkins University -
Washington University - Barnes-Jewish Hospital -
Johns Hopkins University School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1992723936 | |
| NPPES Provider LastName | HAHN | |
| NPPES Provider FirstName | BEVRA | |
| NPPES Provider ZIPCode | 900950001 | |
| NPPES Provider State | CA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 224.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992723936 |
| Last Name Of The Provider | HAHN |
| First Name Of The Provider | BEVRA |
| View All |
Similar Doctors
|
|
Dr. Ernest Brahn, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew L. Sofer, MD |
|
|
Dr. William Stohl, MD |
|
|
Dr. Muhammed Wahab, MD |
|
|
Dr. Dinesh M. Shah, MD |
|
|
Dr. Jacob B. Pelta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Lloyd, MD
This Doctor is OpenDoctor Recommended.
|